Zenas BioPharma, Inc. (ZBIO)

Zenas BioPharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022
Period Ending	Feb 27, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Market Capitalization	1,414	342	-	-
Enterprise Value	1,124	-44	-	-
Last Close Price	26.35	8.19	-	-
PS Ratio	94.30	68.45	-	-
PB Ratio	5.66	1.10	-	-
P/TBV Ratio	7.20	1.10	-	-
Debt / Equity Ratio	0.00	0.00	0.87	0.03
Net Debt / Equity Ratio	-1.48	-1.12	-1.47	-1.37
Net Debt / EBITDA Ratio	1.48	2.14	1.32	0.87
Net Debt / FCF Ratio	1.83	2.92	1.17	1.00
Asset Turnover	0.04	0.02	0.70	-
Quick Ratio	5.57	6.12	2.44	2.59
Current Ratio	5.66	6.21	2.57	2.64
Return on Equity (ROE)	-68.33%	-93.22%	-102.89%	-
Return on Assets (ROA)	-33.72%	-46.76%	-23.77%	-
Return on Capital Employed (ROCE)	-72.60%	-52.40%	-60.40%	-154.70%
Earnings Yield	-13.43%	-45.87%	-	-
FCF Yield	-11.21%	-35.00%	-	-
Buyback Yield / Dilution	-1252.33%	-762.01%	-2.61%	-

Updated Nov 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q